86 related articles for article (PubMed ID: 8855985)
1. 17β-Hydroxysteroid dehydrogenase type 14 is a predictive marker for tamoxifen response in oestrogen receptor positive breast cancer.
Sivik T; Gunnarsson C; Fornander T; Nordenskjöld B; Skoog L; Stål O; Jansson A
PLoS One; 2012; 7(7):e40568. PubMed ID: 22792371
[TBL] [Abstract][Full Text] [Related]
2. 4-protein signature predicting tamoxifen treatment outcome in recurrent breast cancer.
De Marchi T; Liu NQ; Stingl C; Timmermans MA; Smid M; Look MP; Tjoa M; Braakman RB; Opdam M; Linn SC; Sweep FC; Span PN; Kliffen M; Luider TM; Foekens JA; Martens JW; Umar A
Mol Oncol; 2016 Jan; 10(1):24-39. PubMed ID: 26285647
[TBL] [Abstract][Full Text] [Related]
3. [A Case of Multicentric HER2-Positive Breast Cancer with Alterations of the Intrinsic Subtype].
Kikukawa Y; Kawajiri H; Tanda H; Sakimura C; Tendo M; Hori T; Nakata B; Ishikawa T; Hirakawa K
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1842-1844. PubMed ID: 38303226
[TBL] [Abstract][Full Text] [Related]
4. Long-term clinical outcome of oestrogen receptor-positive operable primary breast cancer in older women: a large series from a single centre.
Syed BM; Al-Khyatt W; Johnston SJ; Wong DW; Winterbottom L; Kennedy H; Green AR; Morgan DA; Ellis IO; Cheung KL
Br J Cancer; 2011 Apr; 104(9):1393-400. PubMed ID: 21448163
[TBL] [Abstract][Full Text] [Related]
5. HORMONET: a phase II trial of tamoxifen for estrogen/progesterone receptor-positive neuroendocrine tumors.
Barros MJ; Strosberg J; Al-Toubah T; de Jesus VHF; Durant L; Mello CA; Felismino TC; De Brot L; Taboada RG; Donadio MD; Riechelmann RP
Ther Adv Med Oncol; 2023; 15():17588359231186041. PubMed ID: 37529158
[TBL] [Abstract][Full Text] [Related]
6. Why does hormonal contraception and menopausal hormonal treatment have such a small effect on breast cancer risk?
Eden JA
Aust N Z J Obstet Gynaecol; 2024 Apr; ():. PubMed ID: 38686660
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Tools for Older Women with Breast Cancer: A Systematic Review.
Record SM; Chanenchuk T; Parrish KM; Kaplan SJ; Kimmick G; Plichta JK
Medicina (Kaunas); 2023 Aug; 59(9):. PubMed ID: 37763695
[No Abstract] [Full Text] [Related]
8. Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer.
Yu KD; Jiang YZ; Hao S; Shao ZM
BMC Med; 2015 Oct; 13():254. PubMed ID: 26437901
[TBL] [Abstract][Full Text] [Related]
9. TFF3 is a valuable predictive biomarker of endocrine response in metastatic breast cancer.
May FE; Westley BR
Endocr Relat Cancer; 2015 Jun; 22(3):465-79. PubMed ID: 25900183
[TBL] [Abstract][Full Text] [Related]
10. Trefoil factor 1 in early breast carcinoma: a potential indicator of clinical outcome during the first 3 years of follow-up.
Markićević M; Džodić R; Buta M; Kanjer K; Mandušić V; Nešković-Konstantinović Z; Nikolić-Vukosavljević D
Int J Med Sci; 2014; 11(7):663-73. PubMed ID: 24843314
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcome of adjuvant endocrine treatment according to Her-2/neu status in breast cancer.
James R; Thriveni K; Krishnamoorthy L; Deshmane V; Bapsy PP; Ramaswamy G
Indian J Med Res; 2011 Jan; 133(1):70-5. PubMed ID: 21321422
[TBL] [Abstract][Full Text] [Related]
12. Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening.
Rhodes A; Jasani B; Balaton AJ; Barnes DM; Miller KD
J Clin Pathol; 2000 Sep; 53(9):688-96. PubMed ID: 11041059
[TBL] [Abstract][Full Text] [Related]
13. New generation aromatase inhibitors in breast cancer. Weighing out potential costs and benefits.
Higa GM
Pharmacoeconomics; 2000 Feb; 17(2):121-32. PubMed ID: 10947336
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries.
Rhodes A; Jasani B; Balaton AJ; Miller KD
J Clin Pathol; 2000 Apr; 53(4):292-301. PubMed ID: 10823126
[TBL] [Abstract][Full Text] [Related]
15. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems.
Rhodes A; Jasani B; Barnes DM; Bobrow LG; Miller KD
J Clin Pathol; 2000 Feb; 53(2):125-30. PubMed ID: 10767828
[TBL] [Abstract][Full Text] [Related]
16. Association of pS2 (TFF1) release with breast tumour proliferative rate: in vitro and in vivo studies.
Reshkin SJ; Tedone T; Correale M; Mangia A; Casavola V; Paradiso A
Cell Prolif; 1999; 32(2-3):107-18. PubMed ID: 10535357
[TBL] [Abstract][Full Text] [Related]
17. Development and evaluation of a competitive time-resolved immunofluorometric assay for the estrogen-regulated protein pS2.
Rosenberg Zand RS; Jenkins DJ; Diamandis EP
J Clin Lab Anal; 1999; 13(5):241-5. PubMed ID: 10494134
[TBL] [Abstract][Full Text] [Related]
18. pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients.
Soubeyran I; Quénel N; Coindre JM; Bonichon F; Durand M; Wafflart J; Mauriac L
Br J Cancer; 1996 Oct; 74(7):1120-5. PubMed ID: 8855985
[TBL] [Abstract][Full Text] [Related]
19. Variation of hormonal receptor, pS2, c-erbB-2 and GSTpi contents in breast carcinomas under tamoxifen: a study of 74 cases.
Soubeyran I; Quénel N; Mauriac L; Durand M; Bonichon F; Coindre J-M
Br J Cancer; 1996 Mar; 73(6):735-43. PubMed ID: 8611373
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
